Fig. 3: The efficiency of the FERscore in predicting the sensitivity of breast cancers to ferroptosis.
From: Efficacy of FERscore in predicting sensitivity to ferroptosis inducers in breast cancer
A FERscores in parental and lapatinib-induced persister BT474 cells. B FERscores in the luminal androgen receptor (LAR) and non-LAR subtypes of triple-negative breast cancer. FERscores in parental, tamoxifen-resistant and fulvestrant-resistant (C) T47D and (D) MCF7 cells. E FERscores in T47D and MCF7 cells treated with endocrine drugs after a short time. F, G FERscores in ER+ breast cancer patients before and after neoadjuvant endocrine therapy (baseline: pretreatment, mid: after 10–14 days Letrozol, post: after 90 days Letrozol in GSE20181; NAET-Tam: after a median duration of tamoxifen for 20.7 ± 9.6 days in GSE147271). The distribution of FERscores for (H) breast cancer cell lines (data from CCLE) and (I, J) breast cancer patients (data from METABRIC dataset) across different subtypes. For (J), Chischisq-test were used. K Kaplan-Meier (KM) plot of the differential prognosis between breast cancer patients in groups of high or low FERscores. For figures (A–I), box-and-whisker plots indicate median; 25th and 75th percentiles; whiskers, minima and maxima of the distributions; and the Wilcoxon signed rank test was used. For (K), a log-rank test is used to compare the difference in overall survival.
